Based on all available evidence so far, the honest answer is probably yes, but we must reiterate that RethinkX is not a healthcare or medical research institution and we are not doctors. Nothing we have written constitutes as medical advice. Formal long-term safety data in healthy adults are still accumulating, and caution is appropriate.
The individual safety profiles of each drug class give reason for optimism. GLP-1 drugs have now been used by tens of millions of people across more than a decade, with a well-characterized side effect profile of primarily mild gastrointestinal issues and no signal of serious systemic harm in the major cardiovascular outcome trials. Myostatin/activin blockers have been through extensive Phase 2 and Phase 3 testing in patient populations with serious muscle diseases, again without alarming safety signals.
The combination of GLP-1 plus myostatin/activin blocker specifically is the focus of active clinical trials. Regeneron's COURAGE trial Phase 2 interim results, presented in 2025, showed that the combination of semaglutide with myostatin/activin blockers helped preserve lean mass while increasing fat loss, with no reported serious adverse events. Early human data from multiple laboratories is encouraging.
These drugs also work through two different biological pathways (GLP-1 acts on satiety and metabolic hormones; myostatin/activin blockers act on muscle growth signaling) with no obvious pharmacological interactions. Unlike combining, say, two stimulants or two immunosuppressants, combining a hormone mimetic with a muscle-growth signal modulator does not generate obvious reasons for synergistic toxicity.
Furthermore, large numbers of individuals in bodybuilding and biohacking communities are already self-administering these combinations, sourced through gray and black markets. While these communities have high tolerance for risk and their anecdotal reports should be interpreted cautiously, the absence of a widespread alarm signal from these populations is at least weakly reassuring. Especially since these groups tend to use higher doses with less medical supervision than any clinical trial would.
That said, "safe based on current evidence" is not the same as "fully characterized for long-term use in healthy adults." Muscle mass changes have systemic implications for bone density, cardiovascular geometry, insulin sensitivity, and hormonal regulation. Changes at scale in a healthy adult population are different from changes in patients with rare diseases who formed the original trial populations. The field will benefit substantially from more rigorous long-term safety data, and responsible clinical use will involve ongoing monitoring.
We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.
The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.
Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.
Learn more about the HOT disruption and its implications for health, society, and the economy.
Disclaimer
The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.